Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Despite positive data, the study authors call for prospective validation before PRO burden is incorporated into broader risk-stratification approaches.

The study authors indicated that future investigations could further facilitate clinical decision-making regarding these regimens’ effectiveness.

The increasingly complex CLL treatment landscape will require continued real-world study to guide sequencing decisions.

The BTK inhibitor also showed fewer severe adverse events and better patient-reported quality of life than chemoimmunotherapy.

Higher CCI scores, prior infection, and prior prophylactic anti-infective treatment were associated with greater risk of subsequent infection in both cancers.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

Kerry Rogers, MD, unpacks why patients often misread CAR T-cell therapy in CLL as a guaranteed cure, and what the data really show.

These results provide support for a potential new standard of care in the relapsed/refractory setting.

This research reinforces that fixed-duration, chemotherapy-free regimens can offer both a tolerability and a patient-experience advantage over CIT.

Kerry Rogers, MD, at The James, unpacks what these questions mean for patient counseling and clinical trial equity in chronic lymphocytic leukemia (CLL).

Kerry Rogers, MD, weighs sequencing risk against daily adverse effects like bruising and joint pain that quietly influence BTK inhibitor decisions.

Kerry Rogers, MD, discusses financial toxicity, equitable access to BTK inhibitors, and how frailty shapes CLL clinical trial design.

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.

Adam Kittai, MD, reviews AMPLIFY data supporting acalabrutinib-venetoclax (AV) for CLL, citing strong safety and survival outcomes for select patients.

Kerry Rogers, MD, outlines the cardiovascular risks of prolonged BTK inhibitor therapy in CLL and the major sequencing questions that remain unanswered.

A Medicare claims analysis found zanubrutinib was associated with significantly longer treatment duration and overall survival vs acalabrutinib and ibrutinib.

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short.

This new analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type chronic lymphocytic leukemia.

Kerry Rogers, MD, examines the underemphasized BTK inhibitor adverse effects that quietly erode patient quality of life—and what to do about them.

CLL’s intrinsic immune dysfunction spans humoral, cellular, and innate defects, persisting even with targeted therapy.

Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens.

Data over 17 years from a new analysis contrast prior research in this area, but remain promising on the use of intravenous immunoglobulin in this hematologic cancer.

Kerry Rogers, MD, breaks down the clinical and lifestyle factors that drive frontline treatment selection between BTK inhibitors and venetoclax regimens.

This new analysis highlights zanubrutinib’s survival benefits and lower cardiac toxicity in chronic lymphocytic leukemia.